Core Insights - Akari Therapeutics is presenting data on its novel antibody drug conjugate (ADC) payload, PH1, at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting, highlighting its immune mechanism-of-action and potential in oncology [1][2] Company Overview - Akari Therapeutics is focused on developing next-generation spliceosome payload ADCs, with its lead candidate, AKTX-101, targeting the Trop2 receptor on cancer cells [5][6] - The PH1 payload is designed to disrupt RNA splicing within cancer cells, showing preclinical efficacy in inducing cancer cell death and activating immune cells [5][6] Research Findings - The abstract presented at SITC indicates that the PH1 ADC, in combination with anti-PD-1, resulted in a higher rate of complete tumor regressions compared to a first-in-class ADC with a microtubule inhibitor payload [2] - The immune response stimulated by the PH1 ADC is attributed to neoantigen activation, which enhances the activity of antigen-presenting cells, B, and T-cells [2] - Notably, the combination of PH1 ADC and anti-PD-1 expanded the population of gamma-delta T cells, which are effective in tumor killing [2] Presentation Details - The oral and poster presentations will take place on November 7 and 9, 2025, at the Gaylord National Resort and Convention Center, with specific times and locations provided for attendees [3][4]

Core Insights - Akari Therapeutics is presenting new data on its novel antibody drug conjugate (ADC) payload, PH1, at the 40th Annual SITC Meeting, highlighting its immune mechanism-of-action and potential in oncology treatment [1][2]. Company Overview - Akari Therapeutics is focused on developing next-generation spliceosome payload ADCs, with its lead candidate, AKTX-101, targeting the Trop2 receptor on cancer cells [5]. - The PH1 payload is a spliceosome modulator designed to disrupt RNA splicing in cancer cells, showing preclinical efficacy in inducing cancer cell death and activating immune responses [5]. Research Findings - The abstract presented at SITC indicates that the PH1 ADC, in combination with anti-PD-1, resulted in a higher rate of complete tumor regressions compared to a first-in-class ADC with a microtubule inhibitor payload [2]. - The immune response stimulated by the PH1 ADC involves neoantigen activation, antigen-presenting cells, and T-cell activation, leading to enhanced therapeutic potential [2]. Presentation Details - The oral and poster presentations will provide further insights into the findings, with specific sessions scheduled for November 7 and November 9, 2025 [3][4].

Core Insights - Akari Therapeutics has filed two new provisional patent applications with the USPTO, focusing on its novel immuno-oncology payload PH1 and its combination therapy with other immuno-oncology drugs [1][2][3] Patent Applications - The first patent application protects Akari's novel immuno-oncology payload PH1, which is a Thailanstatin analog, and its mechanism of action that activates the host immune system against cancer [1] - The second application covers a combination therapy of PH1 ADCs with other immuno-oncology drugs that alleviate checkpoint inhibition, demonstrating synergy in preclinical models [1][3] Strategic Goals - The patent filings are part of Akari's strategy to establish a new class of immuno-oncology ADC therapies, building on the success of checkpoint inhibitors [2] - The company aims to enhance its intellectual property estate to create long-term value for itself and potential partners [2] Clinical Implications - Akari's data suggest the potential for a new ADC paradigm targeting cancer through spliceosome modulation, which could improve clinical outcomes compared to existing therapies [4] - Checkpoint inhibitors currently benefit only 20-30% of patients, indicating a significant opportunity for Akari's innovative approach [4] Pipeline Development - Akari is expanding its ADC pipeline to include multiple targets, such as AKTX-101 (Trop2 ADC with PH1 payload) and future programs like AKTX-102 [5][6] - The lead candidate AKTX-101 has shown significant activity and prolonged survival in preclinical studies, with potential synergy with checkpoint inhibitors [6]

Core Insights - Akari Therapeutics has announced promising preclinical data for its novel antibody drug conjugate (ADC) payload, PH1, which targets the AR-V7 receptor linked to hormone refractory prostate cancer progression [1][2][3] Group 1: Product Development - PH1 has shown the ability to suppress AR-V7 receptor expression in a hormone-refractory metastatic castration resistant prostate cancer (mCRPC) model, indicating its potential effectiveness where current therapies fail [3] - In hormone-sensitive LnCAP cells, PH1 demonstrated single-agent benefits and additive effects when combined with existing therapies like Xtandi and Erleada, suggesting potential for first-line combination regimens [4] - The company aims to develop PH1 ADCs as either first-line therapies with ARPIs or second-line therapies for patients who have failed ARPI treatments [5] Group 2: Market Context - There is a significant unmet need for effective therapies in ARPI-resistant hormone refractory prostate cancer, as current options are limited primarily to traditional chemotherapy [2] - Current first-line therapies, including enzalutamide (Xtandi), apalutamide (Erleada), and darolutamide (Nubeqa), have substantial annual sales, indicating a lucrative market for effective alternatives [2] Group 3: Company Overview - Akari Therapeutics specializes in developing next-generation spliceosome payload ADCs, with its lead candidate, AKTX-101, targeting the Trop2 receptor and utilizing a novel PH1 payload [6] - The company’s innovative ADC discovery platform allows for the generation and optimization of ADC candidates tailored to specific targets, enhancing its competitive edge in oncology [6][7]

Core Insights - Akari Therapeutics has announced promising preclinical data for its novel antibody drug conjugate (ADC) payload, PH1, which targets the AR-V7 receptor linked to hormone refractory prostate cancer progression [1][2][3] Group 1: Product Development - The ADC payload PH1 has shown the ability to suppress AR-V7 receptor expression in a hormone-refractory metastatic castration resistant prostate cancer (mCRPC) model, indicating its potential effectiveness where current therapies fail [3][4] - In a hormone-sensitive model, PH1 demonstrated single-agent benefits and additive effects when combined with existing therapies like Xtandi and Erleada, suggesting potential for first-line combination regimens [4][5] - Akari aims to develop the first ADC therapeutic for prostate cancer, targeting both first-line and second-line treatment scenarios for AR-V7 driven tumors [5] Group 2: Market Context - There is a significant unmet need for effective therapies in ARPI-resistant hormone refractory prostate cancer, as current options are limited primarily to traditional chemotherapy [2][4] - Current first-line therapies, including enzalutamide, apalutamide, and darolutamide, have substantial annual sales, indicating a lucrative market for effective alternatives [2] Group 3: Company Overview - Akari Therapeutics specializes in developing next-generation spliceosome payload ADCs, with a focus on innovative therapeutic mechanisms that differ from traditional ADCs [6][7] - The lead candidate, AKTX-101, targets the Trop2 receptor and utilizes a proprietary linker to deliver the PH1 payload directly into tumors, aiming for enhanced efficacy and survival outcomes [6][7]